Kadmon Investors and Media

Investors

Press Releases

Press Releases

Kadmon Announces Pivotal Trial Data Published in the Journal Blood for REZUROCK™ (Belumosudil) in Chronic Graft-Versus-Host Disease (cGVHD)

- REZUROCK is approved by the U.S. FDA for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy - NEW YORK, NY / ACCESSWIRE / July 19, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that data from the... Read More

U.S. FDA Grants Full Approval of REZUROCK™ (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)

- REZUROCK is approved for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy - - Kadmon to Host Conference Call on Monday, July 19, 2021 at 8:00 a.m. ET - NEW YORK, NY / ACCESSWIRE / July 16, 2021   /   Kadmon... Read More

Kadmon to Present at Upcoming Investor Conferences

NEW YORK, NY / ACCESSWIRE / May 25, 2021   /   Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced that Harlan W. Waksal , M.D., President and Chief Executive Officer, will present at the following virtual investor conferences: Jefferies Virtual Healthcare Conference Date: Tuesday, June 1, 2021... Read More

Kadmon to Present Initial Safety Data from Phase 1 Study of KD033 at the 2021 American Society of Clinical Oncology Annual Meeting

- Results Demonstrate KD033 was Well Tolerated in All Patients through Initial Dose Cohorts, Allowing for Continuation of Dose Escalation - NEW YORK, NY / ACCESSWIRE / May 19, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced initial safety data from the ongoing Phase 1 clinical trial of... Read More

Kadmon Provides Business Update and Reports First Quarter 2021 Financial Results

NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the first quarter of 2021. "We continue to ramp up commercial launch preparation activities for belumosudil in anticipation of the PDUFA... Read More

Kadmon Announces Publication of Phase 2a Clinical Trial Results of Belumosudil for cGVHD in the Journal of Clinical Oncology

NEW YORK, NY / ACCESSWIRE / April 21, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the publication of results from KD025-208, the Phase 2a clinical trial of belumosudil (KD025) for chronic graft-versus-host disease (cGVHD). The results were published in the Journal of Clinical... Read More

Kadmon Doses First Patient in Open-Label Phase 2 Clinical Trial of Belumosudil in Systemic Sclerosis

NEW YORK, NY / ACCESSWIRE / April 1, 2021 /   Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the first patient has been dosed in an open-label Phase 2 clinical trial of belumosudil, the Company's ROCK2 inhibitor, in patients with diffuse cutaneous systemic sclerosis (dcSSc), a chronic... Read More

Kadmon Announces Trial-In-Progress Poster on KD033 at the 2021 American Association for Cancer Research Annual Meeting

NEW YORK, NY / ACCESSWIRE / March 25, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present a trial-in-progress poster on KD033-101, the Company's ongoing dose-escalation, dose-expansion trial of KD033 in patients with metastatic and locally advanced solid tumors, at the 2021... Read More

Kadmon Announces U.S. FDA Has Extended the Review Period for Belumosudil in Chronic Graft-Versus-Host Disease

NEW YORK, NY / ACCESSWIRE / March 10, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for belumosudil for the treatment of chronic graft-versus-host disease (cGVHD).... Read More

Kadmon Provides Business Update and Reports Fourth Quarter 2020 Financial Results

NEW YORK, NY / ACCESSWIRE / March 4, 2021 /   Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the fourth quarter and full year ended December 31, 2020 . "With the acceptance of Kadmon's new drug application for belumosudil in... Read More
Displaying 1 - 10 of 16